Is talazoparib/talazopanib already covered by medical insurance? Medical insurance reimbursement policy and the latest developments in 2025

Talazoparib is a polyADP-ribose polymerase (PARP) inhibitor that is mainly used to treat certain types of cancer, especially breast cancer patients with BRCA1 or BRCA2 gene mutations. The drug inhibits the DNA repair mechanism and enhances the sensitivity of tumor cells to chemotherapy and radiotherapy, thereby achieving anti-tumor effects. Talazoparib has clear indications, including the treatment of patients with recurrent breast cancer who have received at least two systemic therapies, especially those who have become resistant to other treatments (such as platinum-based chemotherapy), providing a new treatment option.

In recent years, with the increasing awareness of the importance of BRCA mutations in the occurrence and development of tumors, the demand for talazoparib in clinical application has also increased. Multiple clinical trials have shown that talazoparib has good efficacy in the treatment of breast cancer and can significantly extend the progression-free survival of patients. Therefore, talazoparib is considered an important targeted therapy for specific patient groups, bringing hope to those patients who are difficult to treat.

Regarding the issue of medical insurance, talazoparib is currently on the market in China, but due to its short time on the market, the specific medical insurance coverage is still unclear. Generally speaking, drugs entering the medical insurance catalog need to go through certain evaluation procedures, including efficacy evaluation, economic evaluation, etc. Medical insurance policies may vary depending on region and time. Therefore, it is important for patients to understand the medical insurance policies in their area. The latest information can be obtained through the hospital's pharmacy department or related departments.

In terms of price, the Hong Kong version of the original drug is priced higher.A box of 1mg*30 pills may cost more than 50,000 yuan. This price may be a significant burden for many patients, so when considering this drug, patients should discuss it in detail with their doctor to evaluate the necessity and financial feasibility of treatment.

Reference materials:https://www.talzenna.com/